Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Código da empresaPRPO
Nome da EmpresaPrecipio Inc
Data de listagemJul 18, 2000
CEODanieli (Ilan S)
Número de funcionários54
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 18
Endereço4 Science Park
CidadeNEW HAVEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal06511
Telefone12037877888
Sitehttps://www.precipiodx.com/
Código da empresaPRPO
Data de listagemJul 18, 2000
CEODanieli (Ilan S)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados